Today, TaiMed Biologics announced that its HIV therapy Trogarzo has received a Drug License Collection Notice from the Taiwan Food and Drug Administration. Trogarzo, also known as 佐加洛注射劑, is set to be commercialized in Taiwan through their partner Orient EuroPharma. TaiMed Biologics is listed on the TPEX as 4147, while Orient EuroPharma is listed as 4120. This development marks the completion of the necessary steps for the launch of Trogarzo in Taiwan.